Mineralys Therapeutics(MLYS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company ended 2025 with cash equivalents and investments of $656.6 million, a significant increase from $198.2 million at the end of 2024 [11] - R&D expenses for 2025 were $132 million, down from $168.6 million in 2024, primarily due to a reduction in preclinical and clinical costs [12] - G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024, driven by higher compensation and professional fees [13] - The net loss for 2025 was $154.7 million, an improvement from $177.8 million in 2024 [15] Business Line Data and Key Metrics Changes - The NDA for lorundrostat was accepted by the FDA, with a PDUFA target action date set for December 22, 2026, following five positive clinical trials demonstrating its efficacy [4][5] - The company is focusing on market access planning and payer engagement to ensure the value proposition of lorundrostat is understood [6] Market Data and Key Metrics Changes - Uncontrolled and resistant hypertension affects over 20 million people in the U.S., representing a significant market opportunity for lorundrostat [6] - The company is targeting the third line or later treatment space for lorundrostat, which aligns with the needs of resistant hypertension patients [19] Company Strategy and Development Direction - The company aims to position lorundrostat as a best-in-class therapy for uncontrolled or resistant hypertension, with ongoing evaluations for further clinical development in comorbidities [9] - The strategy includes expanding medical communications and increasing peer-reviewed publications to support the launch of lorundrostat [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the market opportunity for lorundrostat, especially with the upcoming competitive launch by AstraZeneca [18] - The company remains optimistic about payer access and the value proposition of lorundrostat in the resistant hypertension space [19] Other Important Information - The company is exploring additional indications for lorundrostat, particularly in conditions driven by dysregulated aldosterone, such as chronic kidney disease and obstructive sleep apnea [64] - The company is preparing for potential partnerships to maximize the value of lorundrostat, focusing on co-development opportunities [92] Q&A Session Summary Question: What insights are expected from the competitor's launch? - Management is keen to learn about pricing strategies and market positioning from the competitor's launch, emphasizing the large market opportunity for lorundrostat [18] Question: How confident is the company in payer interactions? - Management is optimistic about access, particularly for third-line treatment, and believes the comprehensive dataset will support favorable payer discussions [19] Question: What are the implications of the phase 2 OSA study results? - Management acknowledged the study's limitations but emphasized the importance of demonstrating robust blood pressure reduction in high-risk patients [26][28] Question: What is the commercial capability being built? - The company is expanding its commercial team and medical affairs capabilities to ensure a rapid uptake of lorundrostat upon approval [36] Question: How does the company view potential partnerships? - Management seeks partners that recognize the value of lorundrostat and are willing to engage in co-development opportunities [92]